Home Depot kicked off this week's string of retailer earnings reports. Novo Nordisk provided two major updates on its blockbuster weight-loss drugs. Ukraine President Volodymyr Zelenskyy and European leaders met with President Donald Trump.

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease. Shares climbed roughly 4.5% in Denmark (read more about [weight-loss drugs' s

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended this month. Novo Nordisk faces near-term challenges from semaglutide compounders and Eli Lilly, but the recent FDA approval for MASH and international expansion offer new growth avenues.

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.